SLRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Acelyrin has the GF Value Rank of 0.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Acelyrin's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Shao-lee Lin | director, officer: Chief Executive Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Gil M Labrucherie | officer: Interim CFO | 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Beth C Seidenberg | director, 10 percent owner | |
Henry O Gosebruch | director | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092 |
Mardi Dier | officer: CFO and CBO | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Mina Kim | officer: Chief Legal & Admin. Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Ronald Oyston | officer: Chief People Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Paul Peloso | officer: Chief Medical Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Daniel J. Becker | director | C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036 |
Westlake Biopartners Fund Ii, L.p. | 10 percent owner | 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361 |
Ayurmaya Capital Management Company, Lp | director, 10 percent owner, other: See Remarks | 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451 |
Sean E Harper | 10 percent owner | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Melanie Gloria | officer: Chief Operating Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Westlake Biopartners Gp Ii, Llc | 10 percent owner | 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361 |
From GuruFocus
By PRNewswire • 12-30-2023
By PRNewswire • 12-28-2023
By PRNewswire • 01-09-2024
By PRNewswire • 01-11-2024
By ACCESSWIRE • 01-05-2024
By PRNewswire • 01-06-2024
By PRNewswire • 01-02-2024
By PRNewswire • 12-29-2023
By PRNewswire • 01-11-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.